Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (746)	3/27/2008 6:19:08 PM
From: tuck	Read Replies (3) of 804

Ah, thanks, got the latest Reader and that did the trick. Well . . . E2 ligase program somewhat behind Rigel's (though here I'm confused . . . Celgene talks of E3 ligases on their website - which is the space Rigel is also playing in -- and of E2 ligases on their pipeline pdf). And CELG may be not much behind in any case. Rigel yapped about this area for years before anything came of it, and now they are merely in hit to lead stage in both partnered programs, perhaps a bit farther on internal ones. JNK inhibitors . . . I get those confused . . . they might be near the front there? Benzopyranes . . . me utterly clueless on competition there. The anti-inflammatory program seems to have made progess; P2 data on 10004 soon? There are competing oral anti-TNF compounds in development, I think. P1 data on 11050 soon (I don't even know what kind of molecule this is)? Barr could also seek to overturn the 501 patent. I'm no lawyer, but it seems the whole S.T.E.P.S. concept is shaky IP. I haven't heard if Barr has divulged its strategy on this IP/regulatory front. Have you? You're almost certainly right that litigation will take longer than the 30 month stay. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next